(NASDAQ:MCRI), The 2025 Third Quarter Marks the Highest-Ever Quarterly Level of Revenue, Net Income and EBITDA in Company's 32 Year History Declares Cash Dividend of $0.30 per Share Payable on December 15, 2025 RENO, Nev., Oct. 21, 2025 (GLOBE NEWSWIRE) — Monarch Casino & Resort, Inc. (Nasdaq: MCRI) (“Monarch” or “the Company”) today reported operating […]
(TSX-V:NRX),(Frankfurt:J90),(Boerse Stuttgart – Freiverkehr:J90),(Boerse Muenchen – Freiverkehr:J90),(OTC US:NRXBF),(Other OTC:NRXBF), TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced that Dr. Ina Sarel, Director of Clinical and Regulatory Affairs, has been invited to speak
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK Highlighting Regulatory and Clinical Leadership in Regenerative Exosome Therapies GlobeNewswire October 21, 2025 TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced that
2025 Third Quarter: — Revenue of $4.0 billion, with organic growth of 2.6% — Net income of $341.3 million; $436.4 million Non-GAAP adjusted — Diluted earnings per share of $1.75; $2.24 Non-GAAP adjusted — Operating income of $530.1 million; Non-GAAP Adj. EBITA of $651.0 million with 16.1% margin Omnicom (NYSE: OMC) today announced results for
Monarch Casino & Resort Reports All-Time Record Quarterly Financial Results GlobeNewswire October 21, 2025 The 2025 Third Quarter Marks the Highest-Ever Quarterly Level of Revenue, Net Income and EBITDA in Company's 32 Year History Declares Cash Dividend of $0.30 per Share Payable on December 15, 2025 RENO, Nev., Oct. 21, 2025 (GLOBE NEWSWIRE) — Monarch
What if the same medication that helps you lose weight could also turn back your biological clock? In a landmark 32-week, double-blind, placebo-controlled trial, researchers found thatsemaglutide (the active ingredient in Ozempic®) reversed biological age by an average of 3.1 years, slowed the pace of aging by nearly 9%, and demonstrated organ-specific rejuvenation. These findings
(NasdaqGM:RAPT), SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In
(TSX-V:ODX.H),(TSX-V:ODX-H), TORONTO, Oct. 21, 2025 (GLOBE NEWSWIRE) — Odyssey Resources Limited (“Odyssey” or the “Company“) (NEX: ODX.H) announces that it has granted an aggregate of 1,820,000 incentive stock options (“Options“) under the Company's share option plan (the “Plan“) to certain directors and officers of the Company, as part of its long term incentive plan (the
Odyssey Resources Grants Incentive Stock Options GlobeNewswire October 21, 2025 TORONTO, Oct. 21, 2025 (GLOBE NEWSWIRE) — Odyssey Resources Limited (“Odyssey” or the “Company“) (NEX: ODX.H) announces that it has granted an aggregate of 1,820,000 incentive stock options (“Options“) under the Company's share option plan (the “Plan“) to certain directors and officers of the Company,
— Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix®with a favorable tolerability profile — Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 arms — Company initiates Part 2 of Phase 1/2 head-to-head versus Shingrix in adults 70 years and older Dynavax Technologies Corporation(Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and